Humana Inc (HUM) Receives $328.94 Average PT from Brokerages
Shares of Humana Inc (NYSE:HUM) have received an average rating of “Buy” from the twenty analysts that are covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $336.06.
A number of analysts have recently commented on HUM shares. Bank of America lifted their price target on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Piper Jaffray Companies lifted their price target on Humana from $326.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, July 6th. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a research note on Saturday, June 2nd. BMO Capital Markets lifted their price target on Humana from $328.00 to $355.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. Finally, Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $329.00 price target on the stock in a research note on Monday, May 28th.
In related news, insider Timothy Alan Wheatley sold 11,468 shares of the company’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $299.40, for a total transaction of $3,433,519.20. Following the completion of the sale, the insider now owns 3,889 shares in the company, valued at $1,164,366.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,752 shares of company stock valued at $16,581,234. Corporate insiders own 0.60% of the company’s stock.
Humana stock traded down $3.20 during midday trading on Wednesday, reaching $334.04. The company’s stock had a trading volume of 519,679 shares, compared to its average volume of 776,794. Humana has a 52 week low of $231.90 and a 52 week high of $339.88. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market cap of $45.68 billion, a PE ratio of 28.72, a P/E/G ratio of 1.65 and a beta of 0.96.
Humana (NYSE:HUM) last released its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The firm had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. During the same quarter in the previous year, the business posted $3.49 earnings per share. analysts expect that Humana will post 14.18 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, September 28th will be issued a dividend of $0.50 per share. The ex-dividend date is Thursday, September 27th. This represents a $2.00 annualized dividend and a dividend yield of 0.60%. Humana’s dividend payout ratio is 17.08%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Article: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.